Takeda Pharmaceutical Co Ltd ADR (TAK) carries a ŷRobot AI score of 45 out of 100. The model's fair value estimate is $17.81, 3.8% below the last close of $18.51. The chart signal reads Bearish.
| Metric | TAK |
|---|---|
| AI score | 45 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $17.81 |
| Upside to fair value | -3.8% |
| Previous close | $18.51 |
| P/E | -54.48 |
| Price / sales | 0.01 |
| Market cap | $60.23B |
| EPS | -0.33 |
| Revenue growth | 5.8% |
| 1-year price change | -4.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 30, 2026, ŷRobot's fair-value model estimates Takeda Pharmaceutical Co Ltd ADR (TAK) at $17.81 against a last close of $18.51, implying 3.8% downside to the model's estimate.
The chart-signal model classifies TAK as Neutral as of Sep 30, 2026, with a signal score of -0.06 on a -1 to 1 scale.
TAK scores 45 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 30, 2026.
TAK trades at -54.5 times earnings and 0.0 times sales as of Sep 30, 2026.
ŷRobot's seasonal forecast curve for TAK reads -4.2% at 30 days, -3.4% at 90 days, and -4.6% at one year as of Sep 30, 2026. Seasonal tendencies are historical patterns, not predictions.
Takeda Pharmaceutical Co Ltd ADR's revenue growth is +5.8% and free-cash-flow growth is -119.8% on the latest reported figures.
TAK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.